GSK3B and Alzheimer disease: Increased activity of GSK3β has been found in the brain of sAD patients (Llorens-Martin et al., 2014) and increased activation of GSK3β is inversely associated with a significant decrease in β-catenin levels in the prefrontal cortex of AD patients (Folke et al., 2019).